Page last updated: 2024-12-05

iminodiacetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Iminodiacetic acid (IDA) is a colorless solid that is used as a chelating agent. IDA can be synthesized through the reaction of chloroacetic acid with ammonia. It is used in the production of various metal complexes, including EDTA (ethylenediaminetetraacetic acid) and NTA (nitrilotriacetic acid). IDA is also used in the removal of heavy metals from wastewater and in the manufacture of detergents and other cleaning products. IDA's chelating properties make it useful in various applications, such as the removal of metal ions from water and the stabilization of metal catalysts. Its ability to bind to metal ions has also led to its use in analytical chemistry and as a reagent in pharmaceutical preparations. IDA has been studied for its potential use in the treatment of heavy metal poisoning, as well as for its ability to inhibit the growth of certain bacteria.'

iminodiacetic acid: used as hepatobiliary imaging agent when labeled with Tc; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

iminodiacetic acid : An amino dicarboxylic acid that is glycine in which one of the hydrogens attached to the nitrogen is substituted by a carboxymethyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID8897
CHEMBL ID461164
CHEBI ID24786
SCHEMBL ID27023
MeSH IDM0051682

Synonyms (81)

Synonym
diglycollamic acid
einecs 205-555-4
ida (chelating agent)
acetic acid, 2,2'-iminobis-
diglycocoll
imda
hsdb 2852
hampshire
nsc 18467
iminodi(acetic acid)
brn 0878499
ida (van)
inchi=1/c4h7no4/c6-3(7)1-5-2-4(8)9/h5h,1-2h2,(h,6,7)(h,8,9
nsc-18467
acetic acid, iminodi-
acetic acid,2'-iminobis-
2,2'-iminodiacetic acid
iminodiacetic acid
142-73-4
iminodiethanoic acid
nsc18467
IDA ,
aminodiacetic acid
wln: qv1m1vq
diglycin
n-(carboxymethyl)glycine
diglykokoll
glycine, n-(carboxymethyl)-
usaf do-55
iminobis(acetic acid)
2-(carboxymethylamino)acetic acid
iminodiacetic acid, 98%
D4A4EF63-9E5B-463B-B8EA-18B1C780931E
2,2'-azanediyldiacetic acid
CHEMBL461164
chebi:24786 ,
I0006
AKOS000119681
A807954
unii-xqm2l81m8z
xqm2l81m8z ,
bis(carboxymethyl)amine
2-[(carboxymethyl)amino]acetic acid
C19911
dtxcid607098
dtxsid2027098 ,
tox21_202743
NCGC00260291-01
cas-142-73-4
STL280498
FT-0627182
FT-0627183
FT-0627185
iminodiacetic acid [mi]
iminodiacetic acid [hsdb]
BP-30074
RP10123
BBL027454
SCHEMBL27023
imino diacetic acid
(carboxymethylamino)acetic acid
imino-diacetic acid
Q-201234
mfcd00004280
F2191-0256
iminodiacetic acid, purum, >=98.0% (t)
iminodiacetic acid agarose, saline suspension
iminodiacetic acid sepharose(r), aqueous ethanol suspension
2,2?-iminodiacetic acid (iminodiacetic acid)
2,2'-iminodiacetic acid;glycine, n-(carboxymethyl)-
BCP25963
Q409357
5-(2-methyl-1,3-thiazol-4-yl)-2-thiophenecarbonylchloride
STR04454
iminodiaceticacid
2,2'-iminodiacetic acid (iminodiacetic acid)
EN300-20035
CS-W013399
HY-W012683
diglykokoll;aminodiacetic acid
Z104476528

Research Excerpts

Effects

Iminodiacetic acid (IDA) has been widely used as an important intermediate in the fine chemical industry.IDA functionality has been introduced on styrene-divinyl benzene co-polymeric beads.

ExcerptReferenceRelevance
"Iminodiacetic acid functionality has been introduced on styrene-divinyl benzene co-polymeric beads and characterized by FT-IR in order to develop weak acid based cation exchange resin. "( Iminodiacetic acid functionalized cation exchange resin for adsorptive removal of Cr(VI), Cd(II), Ni(II) and Pb(II) from their aqueous solutions.
Jain, SK; Khatri, PK; Misra, RK, 2011
)
3.25
"Iminodiacetic acid (IDA) has been widely used as an important intermediate in the fine chemical industry. "( A novel synthesis of iminodiacetic acid: biocatalysis by whole Alcaligenes faecalis ZJB-09133 cells from iminodiacetonitrile.
Cheng, F; Li, FF; Liu, ZQ; Shen, YC; Xu, JM; Xue, YP; You, ZY; Zhang, T; Zheng, YG,
)
1.89

Compound-Compound Interactions

ExcerptReferenceRelevance
" The study demonstrates for the first time that derivatized cellulose particles combined with MALDI-TOF MS represent a simple, economical, and rapid approach to generate serum protein profiles for biomarker identification."( Derivatized cellulose combined with MALDI-TOF MS: a new tool for serum protein profiling.
Bartsch, G; Bernardo, K; Bonn, GK; Feuerstein, I; Horninger, W; Huck, CW; Klocker, H; Kofler, K; Pelzer, A; Rainer, M; Stecher, G,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" After coregistration of the CT/SPECT and the treatment planning CT, HEF dose-response functions during and after RT were generated."( Predictive models for regional hepatic function based on 99mTc-IDA SPECT and local radiation dose for physiologic adaptive radiation therapy.
Cao, Y; Feng, M; Frey, KA; Lawrence, TS; Ten Haken, RK; Wang, H, 2013
)
0.39
" A dose-response model was used to describe the breakthrough curves of the two ions at different initial concentrations."( A monolithic copolymer prepared from N-(4-vinyl)-benzyl iminodiacetic acid, divinylbenzene and N,N'-methylene bisacrylamide for preconcentration of cadmium(II) and cobalt(II) from biological samples prior to their determination by ICP-MS.
Chi, Q; Fang, H; Li, C; Li, M; Li, Q; Ma, H; Wang, M; Zhang, H, 2019
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
chelatorA ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
glycine derivativeA proteinogenic amino acid derivative resulting from reaction of glycine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom.
amino dicarboxylic acid
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.65700.006038.004119,952.5996AID1159521
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.58550.001530.607315,848.9004AID1224841
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency2.351719.739145.978464.9432AID1159509
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (317)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (10.41)18.7374
1990's43 (13.56)18.2507
2000's99 (31.23)29.6817
2010's124 (39.12)24.3611
2020's18 (5.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.15 (24.57)
Research Supply Index5.83 (2.92)
Research Growth Index4.81 (4.65)
Search Engine Demand Index78.23 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.59%)5.53%
Reviews11 (3.26%)6.00%
Case Studies7 (2.08%)4.05%
Observational0 (0.00%)0.25%
Other317 (94.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy [NCT03338062]15 participants (Actual)Interventional2017-06-13Completed
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) [NCT03896646]42 participants (Actual)Interventional2019-10-10Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT03338062 (10) [back to overview]Difference in Functional Reserve of Liver Between Theragnostic SBRT Planning and Standard SBRT Planning
NCT03338062 (10) [back to overview]Duration of Local Control
NCT03338062 (10) [back to overview]Number of Patients With Treatment-Related Adverse Events Grade 3 or Above
NCT03338062 (10) [back to overview]Overall Survival
NCT03338062 (10) [back to overview]Percentage of Participants for Whom Theragnostically Planned Radiation is Chosen for the Radiation Treatment Plan
NCT03338062 (10) [back to overview]Progression Free Survival
NCT03338062 (10) [back to overview]Time to Distant Liver Failure
NCT03338062 (10) [back to overview]Time to Transplant
NCT03338062 (10) [back to overview]Time Until Salvage Treatment
NCT03338062 (10) [back to overview]Change in MELD Score

Difference in Functional Reserve of Liver Between Theragnostic SBRT Planning and Standard SBRT Planning

"The functional reserve of the liver for both standard SBRT planning and theragnostic SBRT planning will be calculated for each patient regardless of which plan was ultimately chosen.~Function reserve of the liver = (number of counts outside 15 Gy isodose line / total number of counts within the liver) * global liver function; where global liver function is the rate of liver uptake (%/min) between 150 to 300 seconds normalized to body surface area (m^2) using the Du Bois method. The difference in functional reserve between the theragnostic plan and the standard plan was calculated for each patient." (NCT03338062)
Timeframe: Day -1 of Radiation Treatment

Intervention%/min/m^2 (Mean)
Theragnostic SBRT Planning0.22
Standard SBRT Planning0.02

[back to top]

Duration of Local Control

"Duration of local control was assessed by calculating the time from on study date to date of local failure. Patients who did not experience local failure were censored at their last evaluation date. Local failure (progressive disease at primary diagnosis site) was evaluated using RECIST v1.1 criteria:~Complete response: Disappearance of all target lesions; Partial response: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter; Stable Disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.~The Kaplan-Meier method was used to determine the median and 95% confidence interval." (NCT03338062)
Timeframe: Up to 15 months

Interventionmonths (Median)
Theragnostic SBRT PlanningNA
Standard SBRT PlanningNA

[back to top] [back to top]

Overall Survival

Overall survival was defined as the time from on study date to death due to any cause. Patients who remained alive were censored at their last known alive date. The Kaplan-Meier method was used to determine the median and 95% confidence interval. (NCT03338062)
Timeframe: Up to 3 years

Interventionmonths (Median)
Theragnostic SBRT Planning23.9
Standard SBRT Planning27.5

[back to top]

Percentage of Participants for Whom Theragnostically Planned Radiation is Chosen for the Radiation Treatment Plan

The percentage of participants for whom theragnostically planned radiation is chosen for the radiation treatment plan over the standard plan will be calculated along with the corresponding exact 95% Binomial confidence interval. (NCT03338062)
Timeframe: Day -1 of Radiation Treatment

Interventionpercentage of participants (Number)
Overall64.3

[back to top]

Progression Free Survival

Progression free survival was defined as the time from on study date to date of recurrence of any type or death from any cause. Patients who did not experience recurrence or death were censored at their last evaluation date. The Kaplan-Meier method was used to determine the median and 95% confidence interval. (NCT03338062)
Timeframe: Up to 15 months

Interventionmonths (Median)
Theragnostic SBRT PlanningNA
Standard SBRT PlanningNA

[back to top]

Time to Distant Liver Failure

Time to distant liver failure was defined as the time from on study date to the date of distant liver failure. Patients who did not experience distant liver failure were censored at their date of last evaluation. The Kaplan-Meier method was used to determine the median and 95% confidence interval. (NCT03338062)
Timeframe: Up to 15 months

Interventionmonths (Median)
Theragnostic SBRT PlanningNA
Standard SBRT PlanningNA

[back to top]

Time to Transplant

Time to transplant was defined as the time from on study date to the date of transplant. Patients who did not receive transplant were censored at their off study date. The Kaplan-Meier method was used to determine the median and 95% confidence interval. (NCT03338062)
Timeframe: Up to 15 months

Interventionmonths (Median)
Theragnostic SBRT PlanningNA
Standard SBRT PlanningNA

[back to top]

Time Until Salvage Treatment

Time until salvage treatment was defined as the time from on study date to the start date of salvage treatment. Patients who did not receive salvage treatment were censored at their off study date. The Kaplan-Meier method was used to determine the median and 95% confidence interval. (NCT03338062)
Timeframe: Up to 15 months

Interventionmonths (Median)
Theragnostic SBRT PlanningNA
Standard SBRT PlanningNA

[back to top]

Change in MELD Score

Model for end-stage liver disease (MELD) score measures the severity of liver dysfunction. MELD scores range from 6 to 40 and are based on lab tests including serum creatinine, total bilirubin, and INR. The higher the number, the worse the liver function. (NCT03338062)
Timeframe: Up to 1 year

,
Interventionunits on a scale (Mean)
Baseline MELD ScoreChange from Baseline to Mid-TreatmentChange from Baseline to 1 MonthChange from Baseline to 3 MonthChange from Baseline to 6 MonthChange from Baseline 12 Month
Standard SBRT Planning10.8-0.41.8-2.0-2.0-1.8
Theragnostic SBRT Planning8.80.40.20.81.01.4

[back to top]